signs

In the midst of continuous anticipation on prices on pharmaceutical products, President Trump signed a decree designed on Monday to reduce regulatory obstacles and return faster than pharmaceutical companies to manufacture their products in the United States, the move also includes plans to exert more pressure on foreign drug manufacturers to comply with quality control […]